Clinical trials: Targeted Therapy
Glioma
Tessa Jowell BRAIN MATRIX - Platform Study
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis.
- Trial name
- BRAIN MATRIX (NCT04274283)
- Testing
- Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
- Where
- 14 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Birmingham
Hematologic Diseases, Bacteremia Sepsis
Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases
The purpose of this study is to evaluate whether the use of direct rapid antibiotic susceptibility test (dRAST), in addition to the current standard antibiotic susceptibility test, can increase the proportion of patients with…
- Trial name
- NCT03611257
- Testing
- dRAST, Current standard method
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- Seoul National University Hospital
Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ?
Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?
Not significantly increased survival in T/T
- Trial name
- NCT02740894
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
B-cell Malignancies
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70…
- Trial name
- NCT03125577
- Testing
- 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Lymphoma, Myeloma
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
This study is for patients who have a type of cancer that expresses the protein CD70, which includes lymphoma (lymph gland cancer), myeloma and solid tumors including some sarcomas and kidney cancers, and the cancer has come back…
- Conditions
- Lymphoma, Myeloma, Solid Tumors, Sarcoma
- Trial name
- CALySSEY (NCT07297160)
- Testing
- Dose Level -1, Dose Level 1 (starting dose level), Dose Level 2
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Breast Cancer, Adherence, Medication
Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors
The purpose of this study is to explore the feasibility and acceptability of a brief, virtual, group-based cognitive-behavioral intervention for breast cancer survivors taking hormonal therapy.
- Trial name
- STRIDE (NCT03837496)
- Testing
- STRIDE, Medication Monitoring Control
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Hematological Toxicity, Targeted Therapy
Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
This multicenter, real-world, observational study will retrospectively and prospectively collect real-world data related to the investigational drugs.
- Conditions
- Hematological Toxicity, Targeted Therapy, Breast Cancer
- Trial name
- NCT06503380
- Testing
- No intervenrion.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Fudan University
CD19-positive Relapsed or Refractory B-cell Malignancies
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic…
- Trial name
- NCT06092047
- Testing
- UTAA09 cells for infusion, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Premature Infant, Oxygen Therapy
SCO2T (Servo vs. Servo)
Most premature babies require oxygen therapy. There is uncertainty about what oxygen levels are the best. The oxygen levels in the blood are measured using a monitor called a saturation monitor and the oxygen the baby breathes is…
- Conditions
- Premature Infant, Oxygen Therapy, Hypoxia, Hyperoxia
- Trial name
- NCT04546568
- Testing
- Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - Leoni plus CLAC, Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Thromboembolism
Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine
Despite the rise in prescriptions for direct oral anticoagulants,Vitamin K antagonists(VKA) remains the most prescribed treatment for treating and preventing long-term thromboembolic events.
- Trial name
- VKA (NCT03914053)
- Where
- France
- Volunteers
- 3,387 people
- Sponsor
- University Hospital, Montpellier
NSCLC
Stereotactic Body Radiotherapy for the Treatment of OPD
HALT is a phase II, randomised multi-centre study with integrated seamless continuation to phase III trial following acceptable safety and feasibility assessment.
- Trial name
- HALT (NCT03256981)
- Testing
- SBRT, TKI
- Where
- 29 sites in France, Italy and 3 more
- Volunteers
- 113 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Leukemia
Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying cell samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer PURPOSE: This research study is studying drug…
- Trial name
- NCT01150058
- Testing
- western blotting, flow cytometry, laboratory biomarker analysis
- Volunteers
- 40 people
- Sponsor
- Children's Oncology Group
Metastatic Soft-tissue Sarcoma
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
To find a recommended dose of attIL2-TIL cell therapy that can be given to participant with either relapsed or metastatic sarcomas (has come back or spread to other parts of the body, respectively).
- Trial name
- NCT06474676
- Testing
- Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Dissociation, Auditory Hallucination
Psychological Therapy for Dissociation, Trauma and Voices: A Single Case Experimental Design
Connection to Environment with Cognitive Therapy (CONNECT): A Single-Case Experimental Design Exploring Dissociative Experiences and Voices Emerging empirical evidence has suggested that dissociation is a robust determinant of…
- Conditions
- Dissociation, Auditory Hallucination, Trauma, Psychological, Psychosis
- Trial name
- CONNECT (NCT04127526)
- Testing
- Connection to Environment with Cognitive Therapy (CONNECT)
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- NHS Greater Glasgow and Clyde
Refractory Status Epilepticus
Application of tDCS Stimulation in Controlling Refractory Status Epilepticus
The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus
- Trial name
- tDCS (NCT06344338)
- Testing
- tDCS stimulation
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Xuanwu Hospital, Beijing
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D).
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma, Follicular Lymphoma Grade 3A
- Trial name
- NCT05326243
- Testing
- CD19-targeted chimeric antigen receptor T-cell
- Where
- 5 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- Pell Bio-Med Technology Co., Ltd.
Histiocytosis, Langerhans Cell Histiocytosis
Histiocytic Disorder Follow-up Study
The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific…
- Conditions
- Histiocytosis, Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai Dorfman Disease
- Trial name
- NCT05915208
- Where
- United States
- Volunteers
- 6,000 people
- Sponsor
- University of Alabama at Birmingham
Rhabdomyosarcoma
Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry
This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment…
- Trial name
- AERO-RMS (NCT06924463)
- Testing
- None AHT
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Lille University
CML, GIST
Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
Background: Long-term or life-long oral targeted therapy might also increase patients' distress, influencing patients' cognitive and life activity function, medication adherence and related care needs.
- Trial name
- NCT03880617
- Where
- Taiwan
- Volunteers
- 297 people
- Sponsor
- National Taiwan University Hospital
B-Cell Lymphoblastic Leukemia/Lymphoma
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies
It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-CD19 universal CAR-NK(UCAR-NK) cells therapy combined with HSCT for B cell hematologic…
- Trial name
- NCT05654038
- Testing
- Anti-CD19 UCAR-NK cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China